TY - JOUR
T1 - Targeting mitochondrial dysfunction using methylene blue or mitoquinone to improve skeletal aging
AU - Poudel, Sher Bahadur
AU - Frikha-Benayed, Dorra
AU - Ruff, Ryan R.
AU - Yildirim, Gozde
AU - Dixit, Manisha
AU - Korstanje, Ron
AU - Robinson, Laura
AU - Miller, Richard A.
AU - Harrison, David E.
AU - Strong, John R.
AU - Schaffler, Mitchell B.
AU - Yakar, Shoshana
PY - 2024/3/25
Y1 - 2024/3/25
N2 - Methylene blue (MB) is a well-established antioxidant that has been shown to improve mitochondrial function in both in vitro and in vivo settings. Mitoquinone (MitoQ) is a selective antioxidant that specifically targets mitochondria and effectively reduces the accumulation of reactive oxygen species. To investigate the effect of long-term administration of MB on skeletal morphology, we administered MB to aged (18 months old) female C57BL/J6 mice, as well as to adult male and female mice with a genetically diverse background (UM-HET3). Additionally, we used MitoQ as an alternative approach to target mitochondrial oxidative stress during aging in adult female and male UM-HET3 mice. Although we observed some beneficial effects of MB and MitoQ in vitro, the administration of these compounds in vivo did not alter the progression of age-induced bone loss. Specifically, treating 18-month-old female mice with MB for 6 or 12 months did not have an effect on age-related bone loss. Similarly, long-term treatment with MB from 7 to 22 months or with MitoQ from 4 to 22 months of age did not affect the morphology of cortical bone at the mid-diaphysis of the femur, trabecular bone at the distal-metaphysis of the femur, or trabecular bone at the lumbar vertebra-5 in UM-HET3 mice. Based on our findings, it appears that long-term treatment with MB or MitoQ alone, as a means to reduce skeletal oxidative stress, is insufficient to inhibit age-associated bone loss. This supports the notion that interventions solely with antioxidants may not provide adequate protection against skeletal aging.
AB - Methylene blue (MB) is a well-established antioxidant that has been shown to improve mitochondrial function in both in vitro and in vivo settings. Mitoquinone (MitoQ) is a selective antioxidant that specifically targets mitochondria and effectively reduces the accumulation of reactive oxygen species. To investigate the effect of long-term administration of MB on skeletal morphology, we administered MB to aged (18 months old) female C57BL/J6 mice, as well as to adult male and female mice with a genetically diverse background (UM-HET3). Additionally, we used MitoQ as an alternative approach to target mitochondrial oxidative stress during aging in adult female and male UM-HET3 mice. Although we observed some beneficial effects of MB and MitoQ in vitro, the administration of these compounds in vivo did not alter the progression of age-induced bone loss. Specifically, treating 18-month-old female mice with MB for 6 or 12 months did not have an effect on age-related bone loss. Similarly, long-term treatment with MB from 7 to 22 months or with MitoQ from 4 to 22 months of age did not affect the morphology of cortical bone at the mid-diaphysis of the femur, trabecular bone at the distal-metaphysis of the femur, or trabecular bone at the lumbar vertebra-5 in UM-HET3 mice. Based on our findings, it appears that long-term treatment with MB or MitoQ alone, as a means to reduce skeletal oxidative stress, is insufficient to inhibit age-associated bone loss. This supports the notion that interventions solely with antioxidants may not provide adequate protection against skeletal aging.
KW - antioxidants
KW - bone
KW - methylene blue
KW - micro-CT
KW - mitoquinone
UR - http://www.scopus.com/inward/record.url?scp=85190174954&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85190174954&partnerID=8YFLogxK
U2 - 10.18632/aging.205147
DO - 10.18632/aging.205147
M3 - Article
C2 - 38535998
AN - SCOPUS:85190174954
SN - 1945-4589
VL - 16
SP - 4948
EP - 4964
JO - Aging
JF - Aging
IS - 6
ER -